Oncotarget Publishes Findings on The Use of miR-31-3p Expression

IntegraGen is a company that specializes in the conversion of sensitive data from the raw biological forms into genomic data in addition to diagnostic tools made for oncology. The company just announced that the search results of an analysis report concerning miR-31-3p expression are in Oncotarget. The publishing is a step forward towards finding treatment for tumor expressed diseases. The title of the article reads Association between miR-31-3p. The publication is a confirmation of good analysis on miR-31-3p expression levels. The patients with RAS type of wild metastatic cancer can be utilized to conduct diagnostic tool with the aim of identifying patients that will benefit from the tests.

Profile of Research

The peer-reviewed article that was published is a huge contribution towards the evidence –based research on the benefits of miR-31-3p tumors that originate from patients who have metastatic colorectal cancer. According to Mr. Yann Gaston-Mathe, the director in charge of Molecular Diagnostic, the publication of the research findings is a step towards accomplishing the benefits of precision in medicine.

Oncotarget Features Cancer Treatment

Colorectal cancer is the world’s third common cancer found in men. In women, it ranks second. Research has been conducted to find viable treatment for this cancer. The therapies have been put in place to deliver the right information to doctors. Oncotarget just featured an article on the latest treatment therapy. That is why Oncotarget is highly regarded. The scientific journal seeks to share vital data concerning treatment and the new research in different sectors of medicine. As a scientific journal that shares information, Oncotarget is published twice in a week. In other scenarios, it can be printed when a demand is made.

Conclusion

Oncotarget has always featured articles based on the seriousness of the content. The panel in charge of editing and publishing is well versed with the requirements that must be met. Oncotarget is manned by Mikhail Blagosklonny, a research scientist. His great leadership has been helpful in growing the data base of the journal. Most medical practitioners are turning to the journal to seek vital data. Through Oncotarget, medical practitioners have found a medium through which they can share vital data on treatment.

Leave a Reply

Your email address will not be published. Required fields are marked *